Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 94 articles: HTML format

Single Articles

September 2025
1. AQUINO IG, DE Almeida PC, Rangel-Coelho JP, DE Castro Raucci LMS, et al
   Influence of Caffeic Acid Phenethyl Ester on Osteoblastic Cell Behavior in Coculture With Breast Adenocarcinoma Cells.
   Anticancer Res. 2025;45:3719-3726.
   PubMed     Abstract available
   
   
   
2. ESKELINEN M, Koskela R, Selander T, Kaarniranta K, et al
   Psychological Stress Versus Outcome in Patients With Breast Disease and Breast Cancer: A Prospective 25-year Follow-up Study in Patients With Breast Cancer Symptoms.
   Anticancer Res. 2025;45:3817-3826.
   PubMed     Abstract available
   
   
   
3. LYRONIS G, Efraimidou E, Zachou ME, Kaprana A, et al
   Impact of Fentanyl and Remifentanil on Immune Response in Breast Cancer Patients Post-surgery.
   Anticancer Res. 2025;45:3761-3771.
   PubMed     Abstract available
   
   
   
4. WAGNER JK, Leinhos F, Kunze CA, Bick U, et al
   Prevalence of Incidental Breast Cancer and Precursor Lesions in Carriers of Pathogenic Germline Variants Undergoing Risk-Reducing Mastectomy.
   Anticancer Res. 2025;45:3749-3760.
   PubMed     Abstract available
   
   
   
5. CIPOLLA C, Gebbia V, DI Stefano V, Messina C, et al
   Opsoclonus-myoclonus Syndrome in a Female Breast Cancer Patient: A Case Report and Literature Review.
   Anticancer Res. 2025;45:4037-4045.
   PubMed     Abstract available
   
   
   
6. SAWA A, Sato R, Matsuo T, Okazaki M, et al
   Paclitaxel-induced Peripheral Neuropathy and Quality of Life: Sub-analysis of the MICHEL Study.
   Anticancer Res. 2025;45:3827-3833.
   PubMed     Abstract available
   
   
   August 2025
7. FUJIYOSHI K, Sugihara R, Miyamoto N, Watanabe Y, et al
   Comparison of Comprehensive Genomic Profiling Testing "Ion Torrent Genexus Sequencer" With FoundationOne.
   Anticancer Res. 2025;45:3479-3486.
   PubMed     Abstract available
   
   
   
8. IIDA K, Iwabuchi E, Miki Y, Hasegawa K, et al
   Detection of Somatostatin Receptors by Ligand Derivative Staining in Breast Tumors.
   Anticancer Res. 2025;45:3221-3230.
   PubMed     Abstract available
   
   
   
9. PARK SH, Yoon DH, Kim J, Park SI, et al
   Deletion of the POLR2J4 Gene in Breast Cancer Cells Promotes Bone Metastatic Tumor Growth.
   Anticancer Res. 2025;45:3263-3273.
   PubMed     Abstract available
   
   
   July 2025
10. CRISPO A, Luongo A, Nocerino D, Cascella M, et al
    Assessment of Breakthrough Cancer Pain Among Female Patients With Cancer: Knowledge, Management and Characterization in the IOPS-MS Study.
    Anticancer Res. 2025;45:3149-3164.
    PubMed     Abstract available
    
    
    
11. KAMYAN D, Elemam NM, Alkhayyal N, Talaat IM, et al
    Unlocking New Frontiers in Breast Cancer: The Role of the Tumor Microenvironment, Cutting-Edge Therapies, and Immunotherapy.
    Anticancer Res. 2025;45:2729-2747.
    PubMed     Abstract available
    
    
    June 2025
12. IORIO V, Delia P, Solazzo AP, Fazio I, et al
    Phase II Study of the Effectiveness of the Germinated Wheat-derived Rigenase Plus Polyhexanide in the Prophylaxis for Hypofractionated Radiation-induced Acute Skin Toxicity in Breast Cancer.
    Anticancer Res. 2025;45:2539-2550.
    PubMed     Abstract available
    
    
    
13. KIM HG, Kang SY, Kim KM, Kim JY, et al
    Combined Biomarkers for Prediction of Immune Checkpoint Inhibitor Response in Patients With Triple-negative Breast Cancer.
    Anticancer Res. 2025;45:2575-2586.
    PubMed     Abstract available
    
    
    
14. HONG SD, Kang MS, Katuwal NB, Ghosh M, et al
    Intratumoral Injection of Allogeneic NK Cell With Chemotherapy in a Triple-negative Breast Cancer Preclinical Model.
    Anticancer Res. 2025;45:2669-2688.
    PubMed     Abstract available
    
    
    
15. LEE IH, Kim EA, Lee SJ, Kang B, et al
    The Role of EMP2 in Triple-negative Breast Cancer.
    Anticancer Res. 2025;45:2417-2427.
    PubMed     Abstract available
    
    
    
16. KOKKONEN K, Utriainen M, Penttinen H, Vehmanen L, et al
    Feasibility of an Exercise Training Program Among Patients With Newly Diagnosed Advanced Breast Cancer.
    Anticancer Res. 2025;45:2605-2618.
    PubMed     Abstract available
    
    
    May 2025
17. RADES D, Bartscht T, Rody A, Yu NY, et al
    Chemotherapy-induced Moderate to Severe Peripheral Neuropathy in Patients Receiving Adjuvant Radiotherapy for Breast Cancer.
    Anticancer Res. 2025;45:2123-2135.
    PubMed     Abstract available
    
    
    
18. TAKADA S, Umehara K, Kanae T, Kimura Y, et al
    Prediction of Severe Anemia and Neutropenia Induced by Abemaciclib in Patients With Breast Cancer.
    Anticancer Res. 2025;45:2171-2183.
    PubMed     Abstract available
    
    
    
19. KIM J, Han Q, Kang BM, Mizuta K, et al
    Combination of Recombinant Methioninase With Rapamycin or Chloroquine Is Synergistic to Highly Inhibit Triple-negative Breast Cancer Cells In Vitro.
    Anticancer Res. 2025;45:1853-1859.
    PubMed     Abstract available
    
    
    
20. ZWICKER F, Raether LP, Klepper R, Hauswald H, et al
    Long-term Outcomes of Helical Tomotherapy in Lymph Node-positive Breast Cancer Following Breast-conserving Surgery.
    Anticancer Res. 2025;45:2025-2040.
    PubMed     Abstract available
    
    
    
21. ESKELINEN M, Koskela R, Selander T, Kaarniranta K, et al
    The Impact of State-trait Anxiety Inventory (STAI) Self-evaluation versus 25-year Outcome: A Prospective Follow-up Study in Patients With Breast Cancer Symptoms.
    Anticancer Res. 2025;45:2161-2169.
    PubMed     Abstract available
    
    
    
22. DICKE J, Hero L, Kuhl S, Goldbrunner R, et al
    Expression of YAP1 and TAZ in Melanoma-, Bronchial- and Breast Carcinoma Brain Metastasis: Primary vs. Relapsed Tumors.
    Anticancer Res. 2025;45:1807-1812.
    PubMed     Abstract available
    
    
    
23. RADES D, Bartscht T, Rody A, Ballegaard M, et al
    Two Scoring Tools to Estimate the Risk of Taxane-induced Peripheral Sensory Neuropathy (PNP) in Patients Irradiated for Non-metastatic Breast Cancer.
    Anticancer Res. 2025;45:2115-2121.
    PubMed     Abstract available
    
    
    April 2025
24. TAKEYAMA H, Manome Y, Koyama M, Yoshii Y, et al
    Sialic Acid-Fibronectin-negative and Vimentin-positive Breast Cancers Have Poor Prognoses due to Epithelial-Mesenchymal Transition.
    Anticancer Res. 2025;45:1617-1629.
    PubMed     Abstract available
    
    
    
25. BHALA R, Cando LF, Verma P, Adesoye T, et al
    Biomarkers Predicting Progression and Prognosis of Ductal Carcinoma In Situ (DCIS).
    Anticancer Res. 2025;45:1305-1328.
    PubMed     Abstract available
    
    
    
26. MIKI M, Inubushi S, Han Q, Inoue S, et al
    Efficacy of Methionine Restriction and the PARP-inhibitor Olaparib and Their Combination on BRCA1 Mutant and Wild-type Triple-negative Breast Cancer Cell Lines.
    Anticancer Res. 2025;45:1367-1372.
    PubMed     Abstract available
    
    
    
27. FUJII T, Nakazawa Y, Aoki M, Tanabe K, et al
    Cardioprotective Effect of Pegfilgrastim on Chemotherapy-induced Cardiotoxicity in Preoperative Chemotherapy for Breast Cancer.
    Anticancer Res. 2025;45:1707-1712.
    PubMed     Abstract available
    
    
    March 2025
28. DE SARKAR S, Banerjee S, Ismail A, Mavadia A, et al
    Male Breast Cancer: A Single Institutional Clinicopathological Profiling.
    Anticancer Res. 2025;45:1097-1104.
    PubMed     Abstract available
    
    
    
29. HAQUE W, Verma V, Mangalampalli N, Schwartz MR, et al
    Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer Patients.
    Anticancer Res. 2025;45:1055-1061.
    PubMed     Abstract available
    
    
    
30. PARK HJ, Namkung HR, Jung SB, Choi KT, et al
    Anticancer Potential of Black Ginseng Extract in a Breast Cancer Cell Xenograft Mouse Model.
    Anticancer Res. 2025;45:1047-1054.
    PubMed     Abstract available
    
    
    February 2025
31. GOERDT L, Stefanovic A, Wirtz R, Karic U, et al
    Correlation of HLA-A and HLA-B/C Expression With ESR1 Expression in Patients With Metastatic Breast Cancer as a Potential Prognosticator of Favorable Distant Disease-free Survival.
    Anticancer Res. 2025;45:445-450.
    PubMed     Abstract available
    
    
    
32. OSHIRO A, Nagahashi M, Togashi Y, Kanaoka H, et al
    Clinical Utility of Sentinel Lymph Node Biopsy Using the Medical Imaging Projection System in Breast Cancer Patients, Including Those Following Neoadjuvant Chemotherapy.
    Anticancer Res. 2025;45:789-796.
    PubMed     Abstract available
    
    
    
33. YEARBY LA, Kotina M, Ohemeng A, Banjara B, et al
    Noncancerous Exosomes Establish a Growth Promoting Paracrine Effect on Triple Negative Breast Cancer Cells.
    Anticancer Res. 2025;45:419-431.
    PubMed     Abstract available
    
    
    
34. MORINAGA S, Han Q, Mizuta K, Kang BM, et al
    Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells 9.9 Fold to Low-dose Ivermectin.
    Anticancer Res. 2025;45:451-455.
    PubMed     Abstract available
    
    
    
35. SHIN D, Yoo JO, Jeong JH, Han YH, et al
    MiR-5586-5p Suppresses Hypoxia-induced Angiogenesis Through Multiple Targeting of HIF-1alpha, HBEGF and ADAM17 in Breast Cancer.
    Anticancer Res. 2025;45:473-489.
    PubMed     Abstract available
    
    
    January 2025
36. SATO A, Masaka S, Aisaka A, Ishibashi I, et al
    Hederagenin Glycoside Isolated from the Pericarps of Akebia quinata Fruits Induces Apoptotic Cell Death in Breast Cancer Cells.
    Anticancer Res. 2025;45:135-144.
    PubMed     Abstract available
    
    
    
37. SATO A, Yabuki A, Sato G, Nemoto H, et al
    Garlic (Allium sativum L.) Organosulfur Compounds Inhibit Breast Cancer Cell Proliferation by Decreasing Steroid Sulfatase Levels.
    Anticancer Res. 2025;45:145-152.
    PubMed     Abstract available
    
    
    
38. COLLERY P, Desmaele D, Harikrishnan A, Veena V, et al
    Impact of Rhenium(I)-Diselenoether Compound on Cell Adhesion, Migration, Invasion Capacities, and MMP-2 Release in MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2025;45:73-79.
    PubMed     Abstract available
    
    
    
39. ZANG M, Zheng J, An X, Li BO, et al
    Eribulin Induction of Immunogenic Cell Death (ICD): Comparison With Other Cytotoxic Agents and Temporal Relationship of ICD Biomarkers.
    Anticancer Res. 2025;45:39-53.
    PubMed     Abstract available
    
    
    December 2024
40. SUGANUMA N, Saito N, Yasukawa M, Yamanaka T, et al
    Exposure to Hypoxic Conditions Up-regulates HER2 in Breast Cancer Cell Lines.
    Anticancer Res. 2024;44:5187-5192.
    PubMed     Abstract available
    
    
    
41. SUGANUMA N, Matsubara Y, Takahashi A, Yamanaka T, et al
    Impact of Warm Ischemia Time on HER2 Expression in Breast Cancer Surgical Specimens.
    Anticancer Res. 2024;44:5225-5230.
    PubMed     Abstract available
    
    
    
42. OZCIVICI E, Mese G
    Comprehensive Analysis of GJB1 in Breast Cancer: Its Implications in Survival and Molecular Mechanisms.
    Anticancer Res. 2024;44:5379-5391.
    PubMed     Abstract available
    
    
    November 2024
43. QUITMEYER B, Emelife C, Klausner H, Gbayisomore O, et al
    Differential Effects of Punicic Acid on Cytotoxicity and Peroxiredoxin Expression in MCF-7 Breast Cancer and MCF-10A Normal Cells.
    Anticancer Res. 2024;44:4751-4759.
    PubMed     Abstract available
    
    
    
44. GIRO A, Passildas-Jahanmohan J, Kossai M, Bidet Y, et al
    Comparison of the Predictive and Prognostic Capacities of Neutrophil, Lymphocyte and Platelet Counts and Tumor-infiltrating Lymphocytes in Triple-negative Breast Cancer: Preliminary Results of the PERCEPTION Study.
    Anticancer Res. 2024;44:4983-4994.
    PubMed     Abstract available
    
    
    
45. CHANTARAAMPORN J, Pothipan P, Sakulterdkiat T, Khiankaew B, et al
    CD47 and Calreticulin Expression in Breast Cancer Subtypes and Anti-CD47 Inhibitory Effects in Macrophage-mediated Phagocytosis.
    Anticancer Res. 2024;44:4929-4940.
    PubMed     Abstract available
    
    
    
46. IKEDA T, Honda CK, Kurozumi S, Yokobori T, et al
    Clinical Significance of FAM83G in Breast Cancer: Association With Triple-negative Subtype and Prognosis.
    Anticancer Res. 2024;44:4877-4883.
    PubMed     Abstract available
    
    
    
47. GOTO W, Henmi S, Matsuda H, Nakata K, et al
    Predictive Value of Immune Activity Changes in Breast Cancer Patients Treated With Dose-dense Neoadjuvant Chemotherapy: A Retrospective Study.
    Anticancer Res. 2024;44:5123-5129.
    PubMed     Abstract available
    
    
    
48. SEKI H, Ishiguro Y, Makino A, Yamaguchi K, et al
    Nomogram Predicting Axillary Lymph Node Dissection Omission After Neoadjuvant Chemotherapy for Node-positive Breast Cancer.
    Anticancer Res. 2024;44:5131-5138.
    PubMed     Abstract available
    
    
    October 2024
49. AHMED ZM, Abouegylah M, Khedr GA, Eich HT, et al
    Radiation-induced Esophagitis in Breast Cancer Patients Treated With Supraclavicular Field Irradiation.
    Anticancer Res. 2024;44:4543-4549.
    PubMed     Abstract available
    
    
    
50. CHU J, DO SI, Kim HS
    Identifying High Recurrence Risk in Breast Carcinoma Patients Through Spatial Transcriptomic Analysis.
    Anticancer Res. 2024;44:4387-4401.
    PubMed     Abstract available
    
    
    
51. UENAKA N, Sato E, Horimoto Y, Kawai S, et al
    CD8-Positive T-Cells Are Key Immune Cells for Predicting the Therapeutic Effect of Neoadjuvant Chemotherapy in Triple-negative Breast Cancer.
    Anticancer Res. 2024;44:4525-4536.
    PubMed     Abstract available
    
    
    
52. YE Y, Wang J, Dillard J, Barsky SH, et al
    Tumor Dormancy Within the Lymphovascular Embolus Is Regulated by Multiple Metabolism-signaling Pathways.
    Anticancer Res. 2024;44:4165-4173.
    PubMed     Abstract available
    
    
    September 2024
53. SATO M, Sato T, Hozumi C, Han Q, et al
    [(11)C]Methionine PET vs. [(18)F]Fluorodeoxyglucose PET Whole-body Imaging to Determine the Extent of Methionine-addiction Compared to Glucose-addiction of Primary and Metastatic Cancer of the Trunk in Patients.
    Anticancer Res. 2024;44:3891-3898.
    PubMed     Abstract available
    
    
    
54. PALUMBO I, Becchetti AG, Perrucci E, Falcinelli L, et al
    Sequential Moderate Hypofractionated Boost in Breast Cancer Patients: A Monoinstitutional Analysis of Late Side Effects.
    Anticancer Res. 2024;44:3965-3971.
    PubMed     Abstract available
    
    
    
55. YANO T, Ono Y, Yoshimura M, Ono T, et al
    Postoperative Radiotherapy Using VMAT for RNI Including IMN in Breast Cancer: Report of Short-term Follow-up.
    Anticancer Res. 2024;44:4011-4018.
    PubMed     Abstract available
    
    
    
56. UCHIYAMA M, Shima H, Kutomi G, Kyuno D, et al
    Prognostic Impact of Human Lymphocyte Antigen (HLA) Class I Expression in Patients With Breast Cancer.
    Anticancer Res. 2024;44:4039-4047.
    PubMed     Abstract available
    
    
    
57. LEE H, Cho YA, Kim DG, Son JY, et al
    Real-world Comparison of P53 Immunohistochemistry and TP53 Mutation Analysis Using Next-generation Sequencing.
    Anticancer Res. 2024;44:3983-3994.
    PubMed     Abstract available
    
    
    August 2024
58. MAIMON O, Nisman B, Broier S, Ben-David I, et al
    The Active Tumor Vaccination in Combination With CDK4/6 Inhibitor Treatment: A Case Report.
    Anticancer Res. 2024;44:3543-3550.
    PubMed     Abstract available
    
    
    
59. LIU M, Koo D, Jiang WG, Ye L, et al
    Oestrogen Represses Noggin Expression by Interfering With BMP/Smad Signalling in ER Positive Breast Cancer.
    Anticancer Res. 2024;44:3355-3364.
    PubMed     Abstract available
    
    
    
60. SAHA S, Croyal M, Huvelin JM, Nazih H, et al
    4-Cholesten-3-one Modified the Lipidome of MDA-MB-231 Cells and Potentiated the Effect of Docetaxel.
    Anticancer Res. 2024;44:3277-3285.
    PubMed     Abstract available
    
    
    
61. TANAKA M, Aoki M, Masuda Y, Yoshinaga Y, et al
    Stromal CD73 Expression in Breast Cancer: Subtype-specific Expression and its Prognostic Significance.
    Anticancer Res. 2024;44:3637-3643.
    PubMed     Abstract available
    
    
    
62. CAROPRESE M, Conson M, Barillaro A, Feoli C, et al
    Neoadjuvant Versus Adjuvant Systemic Therapy in Breast Cancer: A Matched Case-control Study.
    Anticancer Res. 2024;44:3501-3506.
    PubMed     Abstract available
    
    
    
63. NA YM, Park SC, Ryu YJ, Cho JS, et al
    Risk Factors for Non-sentinel Lymph Node Metastasis in HR+/HER2- Breast Cancer With cN0.
    Anticancer Res. 2024;44:3493-3500.
    PubMed     Abstract available
    
    
    
64. MOKBEL K
    Unveiling the Complex Ecosystem of Breast Cancer: Crucial Insights for Patients and Doctors.
    Anticancer Res. 2024;44:3317-3319.
    PubMed     Abstract available
    
    
    
65. CHUNG Y, Chu J, DO SI, Kim HS, et al
    Spatial Transcriptomic Profiling Reveals Gene Expression Characteristics in Lymph Node-positive Breast Carcinoma.
    Anticancer Res. 2024;44:3381-3395.
    PubMed     Abstract available
    
    
    July 2024
66. WOO SH, Jung BC, Kim JY, Lee YH, et al
    PEMF Potentiates Doxorubicin-induced Late G(2) Arrest in MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2024;44:2837-2846.
    PubMed     Abstract available
    
    
    
67. TAO X, Na LI, Hu EX, Wang J, et al
    Clinical Diagnostic Value of circ-ARHGER28 for Breast Cancer and its Effect on MCF 7 Cell Proliferation and Apoptosis.
    Anticancer Res. 2024;44:2877-2886.
    PubMed     Abstract available
    
    
    
68. HEIDINGER M, Egle D, Piscuoglio S, Navarro-Aguadero MA, et al
    Extracellular Vesicle DNA Extraction and Sequencing in Ancient Serum Samples From Patients With Breast Cancer.
    Anticancer Res. 2024;44:2981-2988.
    PubMed     Abstract available
    
    
    
69. NIEDER C, Haukland EC, Mannsaker B
    Return to Work After Breast Cancer Treatment: An Electronic Health Record-based Study in North Norway.
    Anticancer Res. 2024;44:3193-3198.
    PubMed     Abstract available
    
    
    June 2024
70. CHU J, DO SI, Kim HS
    Age-related Differences in Spatially Resolved Transcriptomic Profiles of Patients With Hormone Receptor-positive Breast Carcinoma.
    Anticancer Res. 2024;44:2605-2616.
    PubMed     Abstract available
    
    
    
71. WOO SH, Jung BC, Kim JY, Lee YH, et al
    Pulsed Electromagnetic Field Enhances Caffeic Acid Phenethyl Ester-induced Death of MCF-7 Breast Cancer Cells.
    Anticancer Res. 2024;44:2407-2415.
    PubMed     Abstract available
    
    
    
72. CHANG CM, Pekkle Lam HY
    Intratumoral Microbiota: Unraveling their Oncogenic Impact on Cancer Progression With Focus on Breast Cancer Therapeutic Outcomes.
    Anticancer Res. 2024;44:2271-2285.
    PubMed     Abstract available
    
    
    
73. PIOQUINTO-AVILA E, Gonzalez-Cruz AO, Solis-Estrada J, Hernandez-Juarez J, et al
    Anticancer Activity of HER2-targeting CPP-PTEN-THP Chimeric Proteins.
    Anticancer Res. 2024;44:2567-2575.
    PubMed     Abstract available
    
    
    
74. GUNNELLINI M, Tornincasa A, Montedoro M, Caprodossi A, et al
    Neoadjuvant Treatment for a cT4cN+ HER2+ Breast Cancer: Case Report of a Therapeutic Success.
    Anticancer Res. 2024;44:2755-2758.
    PubMed     Abstract available
    
    
    
75. MOKBEL K, Mokbel K
    Harnessing Micronutrient Power: Vitamins, Antioxidants and Probiotics in Breast Cancer Prevention.
    Anticancer Res. 2024;44:2287-2295.
    PubMed     Abstract available
    
    
    
76. SUGAWARA-KOMATSU K, Fujii T, Kurozumi S, Ishikawa H, et al
    Significance of MUC1 and beta-Catenin Localization in Mucinous Carcinoma of the Breast.
    Anticancer Res. 2024;44:2689-2698.
    PubMed     Abstract available
    
    
    
77. SUWANNALERT P, Panpinyaporn P, Wantanachaisaeng P, Teeppaibul T, et al
    A Potential Combination of Targeting HSP90 and mTOR in Breast Cancer Cell Growth, Migration, and Invasion Through Inhibiting AKT Phosphorylation and F-actin Organization.
    Anticancer Res. 2024;44:2555-2565.
    PubMed     Abstract available
    
    
    
78. RADES D, Janssen S, Narvaez-Wolf CA, Kristiansen C, et al
    Seasonal Impact on Grade >/=2 Dermatitis in Patients With Breast Cancer Undergoing Radiotherapy: A Supplementary Analysis.
    Anticancer Res. 2024;44:2617-2620.
    PubMed     Abstract available
    
    
    
79. OMORI S, Ijichi H, Wakasugi A, Shigechi T, et al
    Association Between Preoperative Osteopenia and Prognosis in Breast Cancer Patients.
    Anticancer Res. 2024;44:2671-2679.
    PubMed     Abstract available
    
    
    
80. AGHIMIEN MO, Kolawole Q, Igbinoba PO, Musa MA, et al
    Non-cytotoxic 3-Acetylcoumarin as an Attractive Target for Human Monoamine Oxidase (HMAO) Enzymes.
    Anticancer Res. 2024;44:2335-2341.
    PubMed     Abstract available
    
    
    May 2024
81. VANNI G, Materazzo M, Lorenzo ND, Tacconi F, et al
    Contrast-enhanced Ultrasound Using Intradermal Microbubble Sulfur Hexafluoride in Non-invasive Axillary Staging in Breast Cancer: Are we Missing a Chance?
    Anticancer Res. 2024;44:2021-2030.
    PubMed     Abstract available
    
    
    
82. GOROBETS O, Keam B, Vinh-Hung V, Nguyen NP, et al
    Twenty-five Years Overall Survival Prognostic Value of the Lymph Node Ratio in De Novo Metastatic Breast Cancer.
    Anticancer Res. 2024;44:1995-2002.
    PubMed     Abstract available
    
    
    
83. CIPOLLA C, Lupo S, Grassi N, Battaglia MC, et al
    The Impact of Neoadjuvant Chemotherapy on Axillary Surgical Management of Patients With Breast Cancer and Positive Axillary Lymph Nodes.
    Anticancer Res. 2024;44:2047-2053.
    PubMed     Abstract available
    
    
    
84. PERRONE E, Taralli S, Pagliara D, Larocca LM, et al
    Breast Relapse of Pediatric B-Cell Acute Lymphoblastic Leukemia After CAR-T Therapy Detected by (18)F-FDG PET/CT.
    Anticancer Res. 2024;44:2243-2245.
    PubMed     Abstract available
    
    
    
85. PSEFTOGAS A, Xanthopoulos K, Siasiaridis A, Poutahidis T, et al
    Inactivation of the Tumor Suppressor CYLD Sensitizes Mice to Breast Cancer Development.
    Anticancer Res. 2024;44:1885-1894.
    PubMed     Abstract available
    
    
    April 2024
86. SATO M, Han Q, Mori R, Mizuta K, et al
    Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methion
    Anticancer Res. 2024;44:1499-1504.
    PubMed     Abstract available
    
    
    
87. CIMPEAN AM, Comsa S, Sturza A, Barb AC, et al
    Validation of Human Bone Marrow-derived Mesenchymal Stem Cells and MCF-7 Breast Cancer Cells Co-culture Using a 3D Perfused Biomimetic Microfluidic Platform.
    Anticancer Res. 2024;44:1441-1453.
    PubMed     Abstract available
    
    
    
88. KITSUYA N, Matsuoka M, Onodera T, Yokota I, et al
    Surgical Resection of Primary Tumor for Bone Metastatic Breast Cancer Patients at Initial Presentation.
    Anticancer Res. 2024;44:1591-1601.
    PubMed     Abstract available
    
    
    
89. RADES D, Kristiansen C, Timke C, Duma MN, et al
    Clinically Significant Dermatitis During Adjuvant Radiotherapy for Invasive Breast Cancer.
    Anticancer Res. 2024;44:1525-1531.
    PubMed     Abstract available
    
    
    
90. ARDAVANIS-LOUKERIS G, Kokkali S, Perdikari K, Karatrasoglou E, et al
    A Real-world Study of Everolimus Plus Aromatase Inhibitor in Hormone Receptor-positive, HER2-negative Advanced Breast Cancer.
    Anticancer Res. 2024;44:1559-1565.
    PubMed     Abstract available
    
    
    March 2024
91. SHIN JK, Kim HS, Yoon S
    Co-treatment With Aripiprazole and Vincristine Sensitizes P-Glycoprotein-Overexpressing Drug-resistant MCF-7/ADR Breast Cancer Cells.
    Anticancer Res. 2024;44:1051-1062.
    PubMed     Abstract available
    
    
    
92. JANG SY, Kim J, Hong E, Yang YJ, et al
    Phloretin Inhibits the Proliferation of Breast Cancer Cells Through the Down-regulation of Estrogen Receptor alpha.
    Anticancer Res. 2024;44:1109-1120.
    PubMed     Abstract available
    
    
    
93. COLLERY P, Prunier C, Dosda E, Viallet J, et al
    Effectiveness of Rhenium(I)-diselenoether Low Doses in a Triple-negative Breast Cancer Chicken Embryo Model.
    Anticancer Res. 2024;44:941-951.
    PubMed     Abstract available
    
    
    
94. YANG DK, Tungalag T, Lee SJ, Kim SJ, et al
    Methyl Jasmonate-induced Increase in Intracellular Magnesium Promotes Apoptosis in Breast Cancer Cells.
    Anticancer Res. 2024;44:1087-1095.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.